-
公开(公告)号：US09822074B2
公开(公告)日：2017-11-21
申请号：US15618182
申请日：2017-06-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Saleem Ahmad , Lidet A. Negash
IPC: C07D211/90 , C07D401/04 , C07D409/04 , C07D409/14 , C07D417/04 , A61K31/4412 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K45/06
CPC classification number: C07D211/90 , A61K31/4412 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D211/78 , C07D211/86 , C07D401/04 , C07D409/04 , C07D409/14 , C07D417/04
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
公开(公告)号：US20230114683A1
公开(公告)日：2023-04-13
申请号：US17792837
申请日：2021-02-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Saleem Ahmad , Lidet A. Negash
IPC: C07D471/04 , C07D471/14
Abstract: Disclosed are compounds of Formulas (I) or (II) or a salt thereof, wherein X, R1, R2, R3, and n are defined herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
-
公开(公告)号：US20200062777A1
公开(公告)日：2020-02-27
申请号：US16612478
申请日：2018-05-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Saleem AHMAD , Ling Li , Lidet A. Negash , John Hynes
IPC: C07D495/04 , C07D409/12
Abstract: Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CR4 or N; Y is CR5 or N; provided that only one of X and Y is N; (R1) is: or; wherein R1, R1a, R1b, R1c, R2, and R3 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
-
公开(公告)号：US20140357670A1
公开(公告)日：2014-12-04
申请号：US14288422
申请日：2014-05-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Saleem Ahmad , Lidet A. Negash
IPC: C07D417/04 , A61K31/4412 , A61K45/06 , C07D401/04 , C07D409/14 , C07D211/78 , C07D409/04
CPC classification number: C07D211/90 , A61K31/4412 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D211/78 , C07D211/86 , C07D401/04 , C07D409/04 , C07D409/14 , C07D417/04
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
Abstract translation: 本发明提供式（I）化合物或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的单酰基甘油酰基转移酶2型（MGAT2）抑制剂。
-
![BENZO[5,6][1,4]DIOXINO[2,3-B]PYRIDINE COMPOUNDS USEFUL AS IRAK4 INHIBITORS](/abs-image/US/2023/03/30/US20230101525A1/abs.jpg.150x150.jpg)
公开(公告)号：US20230101525A1
公开(公告)日：2023-03-30
申请号：US17792741
申请日：2021-02-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Lidet A. Negash , Saleem Ahmad
IPC: C07D491/056
Abstract: Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
-
Patent Agency Ranking
公开(公告)号：US09365558B2
公开(公告)日：2016-06-14
申请号：US14288422
申请日：2014-05-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Saleem Ahmad , Lidet A. Negash
IPC: C07D211/86 , C07D401/08 , C07D401/10 , C07D417/04 , C07D211/78 , A61K31/4412 , C07D409/04 , C07D401/04 , C07D409/14 , A61K45/06 , C07D211/90
CPC classification number: C07D211/90 , A61K31/4412 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D211/78 , C07D211/86 , C07D401/04 , C07D409/04 , C07D409/14 , C07D417/04
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
Abstract translation: 本发明提供式（I）化合物或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的单酰基甘油酰基转移酶2型（MGAT2）抑制剂。
-
![OXABICYCLO [2.2.2] ACID GPR120 MODULATORS](/abs-image/US/2014/09/18/US20140275173A1/abs.jpg.150x150.jpg)
公开(公告)号：US20140275173A1
公开(公告)日：2014-09-18
申请号：US14205421
申请日：2014-03-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Hao Zhang , Peter T.W. Cheng , Sean Chen , Shiwei Tao , Shung C. Wu , Lidet A. Negash
IPC: C07D493/08 , A61K31/427 , A61K45/06 , A61K31/4245 , A61K31/4196 , A61K31/35 , A61K31/4433
CPC classification number: C07D493/08 , A61K31/35 , A61K31/352 , A61K31/4196 , A61K31/4245 , A61K31/427 , A61K31/4433 , A61K45/06 , A61K2300/00
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
Abstract translation: 本发明提供式（I）化合物或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的GPR120G蛋白偶联受体调节剂。
-
公开(公告)号：US20220281844A1
公开(公告)日：2022-09-08
申请号：US17632811
申请日：2020-08-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Saleem Ahmad , Kandhasamy Sarkunam , Ling Li , Lidet A. Negash , John Hynes
IPC: C07D401/14 , C07D401/04 , C07D215/54 , C07D417/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D409/14 , C07D471/04 , C07D213/22 , C07D213/04 , C07D277/22 , C07D213/38
Abstract: Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CR4a or N; Y is CR4b or N; Z is CR4d or N; provided that zero or 1 of X, Y, and Z is N; and R1, R2, R3, R4a, R4b, R4c, and R4d are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
-
公开(公告)号：US10829496B2
公开(公告)日：2020-11-10
申请号：US16612478
申请日：2018-05-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Saleem Ahmad , Ling Li , Lidet A. Negash , John Hynes
IPC: C07D495/04 , C07D409/12
Abstract: Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CR4 or N; Y is CR5 or N; provided that only one of X and Y is N; (R1) is: or; wherein R1, R1a, R1b, R1c, R2, and R3 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
-
公开(公告)号：US20170283381A1
公开(公告)日：2017-10-05
申请号：US15618182
申请日：2017-06-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Saleem Ahmad , Lidet A. Negash
IPC: C07D211/90 , A61K31/4412 , C07D417/04 , C07D409/14 , C07D409/04 , A61K31/4436 , C07D401/04 , A61K31/444 , A61K45/06 , A61K31/4439
CPC classification number: C07D211/90 , A61K31/4412 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D211/78 , C07D211/86 , C07D401/04 , C07D409/04 , C07D409/14 , C07D417/04
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.022 seconds)
